Ine Moors

Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>

Mark J. Levis, Mehdi Hamadani, Brent R. Logan et al. · Journal of Clinical Oncology · 2024 · 185 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial

David A. Sallman, Tessa Kerre, Violaine Havelange et al. · The Lancet Haematology · 2023 · 93 citations · Full text

Medicine, Hematology, Immunology +17

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Bob Löwenberg, Thomas Pabst, Johan Maertens et al. · Blood Advances · 2021 · 66 citations · Full text

Medicine, Oncology, Pharmacology +16

Clinical Impact of Polymerase Chain Reaction–Based <i>Aspergillus</i> and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter Study

Sammy Huygens, Albert Dunbar, Jochem B. Buil et al. · Clinical Infectious Diseases · 2023 · 57 citations · Full text

Medicine, Hematology, Microbiology +17

Stopping antibiotic therapy after 72 h in patients with febrile neutropenia following intensive chemotherapy for AML/MDS (safe study): A retrospective comparative cohort study

Alexander Schauwvlieghe, Albert Dunbar, Emma Storme et al. · EClinicalMedicine · 2021 · 31 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17